Exciting times ahead for sustained novocyt growth11 Apr 2021 11:32
The fall in share price on Friday was dramatic ,oversold and played out by market makers to take out weak share holders . This is how market makers play their games to make money !
The fact remains clear that novocyt have been generating revenues just under £1M / day over Q1 . This is amazing and proves novocyt are way ahead of the game with others trying to still make money. It is a company that is doing brilliant !
Now that novocyt are not extending services for the DHSC , novocyt can and will concentrate more resources , and tap into the private and international market sectors to replace that missing 50% shortfall from the DHSC contract. The world covid-19 diagnostic PCR testing and private sector markets are far more lucrative than this DHSC contract.
There is £70B revenue of covid-19 diagnostic testing to tap into from international and private covid-19 diagnostic testing .
Look at the R&D RNS 24th February 2021 in detail and its exciting read. I have taken an extract from it :
'' Of note, following its launch, our PROmate™ test has been well received by users and opens up new opportunities for rapid PCR testing, including in private testing markets. In addition, we look forward to presenting exciting long-term plans for Novacyt during Q2 this year as we continue to define our strategy for delivering sustainable, long-term growth."